LLY

1,048.7

+1.77%↑

JNJ

202.99

+1.44%↑

ABBV

233.02

-0.35%↓

UNH

309.14

-1.49%↓

AZN

88.99

-0.51%↓

LLY

1,048.7

+1.77%↑

JNJ

202.99

+1.44%↑

ABBV

233.02

-0.35%↓

UNH

309.14

-1.49%↓

AZN

88.99

-0.51%↓

LLY

1,048.7

+1.77%↑

JNJ

202.99

+1.44%↑

ABBV

233.02

-0.35%↓

UNH

309.14

-1.49%↓

AZN

88.99

-0.51%↓

LLY

1,048.7

+1.77%↑

JNJ

202.99

+1.44%↑

ABBV

233.02

-0.35%↓

UNH

309.14

-1.49%↓

AZN

88.99

-0.51%↓

LLY

1,048.7

+1.77%↑

JNJ

202.99

+1.44%↑

ABBV

233.02

-0.35%↓

UNH

309.14

-1.49%↓

AZN

88.99

-0.51%↓

Search

Crinetics Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

42.62 -0.98

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

42.01

Massimo

43.53

Metriche Chiave

By Trading Economics

Entrata

-14M

-130M

Vendite

-888K

143K

Margine di Profitto

-90,972.727

Dipendenti

437

EBITDA

33K

-129M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+86% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

94M

4.1B

Apertura precedente

43.6

Chiusura precedente

42.62

Notizie sul Sentiment di mercato

By Acuity

10%

90%

14 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

18 nov 2025, 19:25 UTC

Acquisizioni, Fusioni, Takeovers

Canada Says Anglo American's Pledges to Secure Teck Resources Deal Not Enough -- 2nd Update

18 nov 2025, 18:09 UTC

Acquisizioni, Fusioni, Takeovers

Canada Says Anglo American's Pledges to Secure Teck Resources Deal Not Enough -- Update

18 nov 2025, 17:39 UTC

Acquisizioni, Fusioni, Takeovers

Canada Says Anglo American's Pledges to Secure Teck Resources Deal Not Enough

18 nov 2025, 16:25 UTC

I principali Market Mover

Diginex Rises on Deal With Digital Asset Platform Evident

18 nov 2025, 23:56 UTC

Discorsi di Mercato

Gold Edges Higher on Likely Technical Recovery -- Market Talk

18 nov 2025, 23:39 UTC

Discorsi di Mercato

Nikkei May Rise on Bargain-Hunting Interest -- Market Talk

18 nov 2025, 22:59 UTC

Discorsi di Mercato

FireFly Metals Can Build Bigger Operation at Green Bay -- Market Talk

18 nov 2025, 22:08 UTC

Discorsi di Mercato

Sandfire's Kalkaroo Project Push Adds to Copper M&A Surge -- Market Talk

18 nov 2025, 22:03 UTC

Acquisizioni, Fusioni, Takeovers

Meta Defeats FTC's Antitrust Case Alleging Social-Media Monopoly -- 3rd Update

18 nov 2025, 22:03 UTC

Utili

These Stocks Moved the Most Today: Nvidia, Microsoft, Home Depot, Cloudflare, Energizer, Honeywell, Medtronic, Klarna, and More -- Barrons.com

18 nov 2025, 21:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

18 nov 2025, 21:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

18 nov 2025, 21:15 UTC

Discorsi di Mercato

Private High-Grade Credit Market Is Changing, BlackRock Says -- Market Talk

18 nov 2025, 20:46 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Edge Up on Weather Outlook -- Market Talk

18 nov 2025, 20:13 UTC

Discorsi di Mercato

Distillate Supply Concerns Pull Crude Futures Higher -- Market Talk

18 nov 2025, 19:48 UTC

Discorsi di Mercato

Gold and Silver Turn Lower on Fed Outlook -- Market Talk

18 nov 2025, 19:19 UTC

Acquisizioni, Fusioni, Takeovers

Anheuser-Busch InBev Nears $700 Million Deal for Party Punch Maker BeatBox -- WSJ

18 nov 2025, 19:19 UTC

Acquisizioni, Fusioni, Takeovers

Anheuser-Busch InBev in Talks to Buy Party Punch Maker BeatBox, Sources Say -- WSJ

18 nov 2025, 19:19 UTC

Acquisizioni, Fusioni, Takeovers

AB InBev-BeatBox Deal Could Come Together Soon, Sources Say -- WSJ

18 nov 2025, 19:19 UTC

Acquisizioni, Fusioni, Takeovers

AB InBev Deal Would Value BeatBox At Around $700M, Sources Say -- WSJ

18 nov 2025, 18:29 UTC

Utili

These Stocks Are Moving the Most Today: Nvidia, Microsoft, Home Depot, Cloudflare, Energizer, Honeywell, Medtronic, Klarna, and More -- Barrons.com

18 nov 2025, 18:18 UTC

Discorsi di Mercato

Ethanol Demand Expected to Boost Corn Futures -- Market Talk

18 nov 2025, 17:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

18 nov 2025, 17:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

18 nov 2025, 17:19 UTC

Discorsi di Mercato
Utili

Good Weather Was Bad News for Home Depot's 3Q -- Market Talk

18 nov 2025, 17:06 UTC

Utili

Medtronic Stock Rises After Earnings. What Caught Investors' Attention. -- Barrons.com

18 nov 2025, 16:06 UTC

Acquisizioni, Fusioni, Takeovers

Intuit Stock Gains on OpenAI Deal. ChatGPT Is Coming to TurboTax. -- Barrons.com

18 nov 2025, 15:59 UTC

Utili

Home Depot Cuts Outlook as Home Improvement Slowdown Continues -- Update

18 nov 2025, 15:35 UTC

Acquisizioni, Fusioni, Takeovers

Eni: Acquisition Adds to Plenitude's Installed-Capacity Targets, Bolsters France Presence

18 nov 2025, 15:35 UTC

Acquisizioni, Fusioni, Takeovers

Eni: Portfolio Comprises Capacity of Around 760MW in Operation

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

86% in crescita

Previsioni per 12 mesi

Media 80 USD  86%

Alto 108 USD

Basso 45 USD

Basato su 15 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

15 ratings

14

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

30.39 / 33.46Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Neutral Evidence

Sentiment

By Acuity

14 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat